Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Sell Good Start Genetics' Carrier Screening Test Service

NEW YORK (GenomeWeb) – Good Start Genetics said today that it has partnered with Roche Diagnostics to sell its carrier screening service for inherited disorders.

Under the agreement, Roche Diagnostics will offer Good Start's GeneVu carrier screening test along with its own Harmony noninvasive prenatal fetal aneuploidy test, which was developed by Ariosa Diagnostics.

"The agreement with Good Start Genetics will enable Roche to offer a broader range of screening services to healthcare professionals who provide care for pregnant women and for parents involved in planning a family," Whitney Green, senior vice president of commercial operations at Roche Diagnostics, said in a statement, adding that GeneVu will complement the Harmony test.

Both GeneVu and Harmony are only available as laboratory-developed tests in the US and have not been approved by the US Food and Drug Administration.

The GeneVu test identifies carriers of a number of inherited genetic disorders. It comes in different versions and uses next-generation sequencing as its underlying technology.

The announcement of the marketing agreement comes about a month after Good Start Genetics said that it is selling its VeriYou test, which screens only for carriers of cystic fibrosis and spinal muscular atrophy, through Amazon.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.